Neuren secures funding for key activities for Rett syndrome
Filed with ASX · · 3 pages · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- Response to ASX Price Query
- Trading Halt
- Investor presentation, 2 June 2017
- Neuren announces grant of two new patents to 2032
- Notice of Annual General Meeting/Proxy Form
Later from Neuren Pharmaceuticals
- Appendix 3B
- Neuren Pharmaceuticals granted Type B Meeting with FDA for Rett syndrome
- Notice of special meeting of shareholders
- Neuren Pharmaceuticals reports 2017 half-year results
- Results of Meeting
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals